The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.
作者信息
Matsuoka Tasuku, Yamamoto Yurie, Yashiro Masakazu
机构信息
Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Institute of Medical Genetics, Osaka Metropolitan University, Osaka, Japan.
出版信息
Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.
Abstract
摘要
Zotero 插件